“Given the considerable time and investment required for additional clinical trials, we find it prudent to explore strategic options,” said Mel Sorensen, M.D., Galera’s President and CEO. “We also made the difficult decision to discontinue our GRECO trials, which we believe is an appropriate step towards cash conservation and maximizing value for our shareholders. We extend our gratitude to all the patients, research teams, and dedicated employees who have contributed to the advances we have made.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GRTX:
- Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
- Galera Therapeutics estimates cash balance of $28.4M as of Sept. 30
- Galera Therapeutics announces review of strategic alternatives
- Galera Therapeutics to discontinue both GRECO trials
- Galera Therapeutics says FDA confirms need for new trial for avasopasem for SOM
